High Frequencies of De Novo CNVs in Bipolar Disorder and Schizophrenia  by Malhotra, Dheeraj et al.
Neuron
ArticleHigh Frequencies of De Novo CNVs
in Bipolar Disorder and Schizophrenia
Dheeraj Malhotra,1,2,22 Shane McCarthy,22 Jacob J. Michaelson,1,2 Vladimir Vacic,15,22 Katherine E. Burdick,23
Seungtai Yoon,5,22 Sven Cichon,10,11,12 Aiden Corvin,17 Sydney Gary,22 Elliot S. Gershon,21 Michael Gill,17
Maria Karayiorgou,18 John R. Kelsoe,2,4,20 Olga Krastoshevsky,19 Verena Krause,19 Ellen Leibenluft,7 Deborah L. Levy,19
Vladimir Makarov,5,22 Abhishek Bhandari,1,2,22 Anil K. Malhotra,6 Francis J. McMahon,14 Markus M. No¨then,10,11,16
James B. Potash,8 Marcella Rietschel,13 Thomas G. Schulze,9 and Jonathan Sebat1,2,3,4,22,*
1Beyster Center for Genomics of Psychiatric Diseases
2Department of Psychiatry
3Department of Cellular Molecular and Molecular Medicine
4Institute for Genomic Medicine
University of California, San Diego, La Jolla, CA 92093, USA
5Seaver Autism Center, Mount Sinai School of Medicine, New York, NY 10029, USA
6Zucker Hillside hospital, North Shore Long Island Jewish health system, Glen Oaks, NY 11004, USA
7Section on Bipolar Spectrum Disorders, Emotion and Development Branch, NIMH Building 15K - MSC 2670, Bethesda, MD 20892, USA
8Department of Psychiatry, University of Iowa, Carver College of Medicine, Iowa City, IA 52242, USA
9Department of Psychiatry and Psychotherapy, George-August-University Gottingen, von-Siebold-Str.5 370075 Gottingen, Germany
10Department of Genomics, Life and Brain Center
11Institute of Human Genetics
University of Bonn, D-53127 Bonn, Germany
12Institute of Neuroscience and Medicine (INM-1), Research Center Julich, D-52425 Julich, Germany
13Central Institute of Mental Health, University of Heidelberg J5, 68159 Mannheim, Germany
14Genetic Basis ofMood andAnxiety Disorders, National Institute ofMental Health, NIH, Convent DriveMSC3719, Bethesda,MD20892, USA
15Department of Computer Science, Columbia University, New York, NY 10027, USA
16German Center for Neurodegenerative Diseases (DZNE), D-53175 Bonn, Germany
17Neuropsychiatric Genetics Research Group, Institute of Molecular Medicine and Department of Psychiatry, Trinity College Dublin,
Dublin 2, Ireland
18Department of Psychiatry, Columbia University, New York, NY 10032, USA
19McLean Hospital, Belmont, MA 02478, USA
20Veterans Affairs San Diego Healthcare System, San Diego, CA 92161, USA
21Department of Psychiatry and Behavioral Neuroscience, University of Chicago, Chicago, IL 60637, USA
22Stanley Institute for Cognitive Genomics, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY 12824, USA
23Mount Sinai School of Medicine, New York, NY 10029, USA
*Correspondence: jsebat@ucsd.edu
DOI 10.1016/j.neuron.2011.11.007SUMMARY
While it is known that rare copy-number variants
(CNVs) contribute to risk for some neuropsychiatric
disorders, the role of CNVs in bipolar disorder is
unclear. Here, we reasoned that a contribution of
CNVs to mood disorders might be most evident for
de novo mutations. We performed a genome-wide
analysis of de novo CNVs in a cohort of 788 trios.
Diagnoses of offspring included bipolar disorder
(n = 185), schizophrenia (n = 177), and healthy
controls (n = 426). Frequencies of de novo CNVs
were significantly higher in bipolar disorder as com-
pared with controls (OR = 4.8 [1.4,16.0], p = 0.009).
De novo CNVs were particularly enriched among
cases with an age at onset younger than 18 (OR =
6.3 [1.7,22.6], p = 0.006). We also confirmed a signifi-
cant enrichment of de novo CNVs in schizophrenia
(OR = 5.0 [1.5,16.8], p = 0.007). Our results suggestthat rare spontaneous mutations are an important
contributor to risk for bipolar disorder and other
major neuropsychiatric diseases.
INTRODUCTION
Bipolar disorder (BD, also known as manic-depressive illness) is
a severe mood disorder consisting of episodes of mania and
depression. The lifetime prevalence of bipolar disorder in the
general population is 1% and the illness is associated with
considerable morbidity and a high lifetime risk of suicide (Meri-
kangas et al., 2011).
Genes play an important role in risk for BD. The rate of concor-
dance formonozygotic twins is 40%, comparedwith a 5% rate in
dizygotic twins (Kendler et al., 1995; Kieseppa¨ et al., 2004;
McGuffin et al., 2003), and risk among the first-degree relatives
of individuals with BD is ten-fold greater than risk among the
general population (Barnett and Smoller, 2009). However, as
with other psychiatric disorders, the genetics of BD is complex,Neuron 72, 951–963, December 22, 2011 ª2011 Elsevier Inc. 951
Figure 1. Detection, Validation, and Breakpoint Sequencing of De Novo CNVs in BD
Representative examples of microarray data and sequencing results are provided for deletions detected in two subjects with diagnoses of BD, 410-10142
(panel I) and 410-10127 (panel II).
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considerable phenotypic heterogeneity of clinical populations
(Potash et al., 2007).
Genetic risk factors with individually large effects are likely to
be rare. Association-based methods to identify common genetic
risk alleles in BD have met with limited success. Early studies
implicated a few common variants with modest effects (Baum
et al., 2008; Ferreira et al., 2008). Robust support for one of these
loci, the L-type calcium channel CACN1AC, has been obtained
in a recent meta-analysis of 11,974 patients and 51,792 controls,
along with new evidence for a second locus, ODZ4 (Sklar et al.,
2011). However, the paucity of significant findings in very large
samples of cases and controls suggests that the contribution
of common genetic variants to heritability of BD is limited.
Alternative approaches that focus on rare genetic variants
are needed. One genetic approach that has been used effec-
tively to overcome some of the problems of heterogeneity is
the genome-wide analysis of rare copy-number variants
(CNVs). Studies from our group (McCarthy et al., 2009; Sebat
et al., 2007; Vacic et al., 2011; Walsh et al., 2008) and from
multiple independent groups (International Schizophrenia
Consortium, 2008; Pinto et al., 2010; Stefansson et al., 2008;
Xu et al., 2008) have now firmly established that rare CNVs
contribute to genetic risk for schizophrenia (SCZ) and autism
spectrum disorder (ASD) and, in particular, that spontaneous
(de novo) CNVs are important risk factors in the sporadic form
of these disorders (Levy et al., 2011; Marshall et al., 2008;
Sanders et al., 2011; Sebat et al., 2007; Xu et al., 2008).
Observations of a similar nature have been made in studies
of BD. CNV loci at 16p11.2 (McCarthy et al., 2009) and 3q29
(Clayton-Smith et al., 2010; Mulle et al., 2010; Quintero-Rivera
et al., 2010) confer risk for multiple psychiatric disorders, and
two studies have found preliminary evidence implicating both
in BD (McCarthy et al., 2009; Quintero-Rivera et al., 2010). Two
studies have demonstrated an enrichment of rare CNVs in
patients with bipolar disorder (Priebe et al., 2011; Zhang et al.,
2009) as compared with healthy controls. In both studies, the
greatest enrichment was observed in subjects with an earlier
disease onset, defined as an age at onset (AAO) < 18 and < 21
in Zhang et al. (2009) and Priebe et al. (2011), respectively.
However, two subsequent studies did not support these findings
(Grozeva et al., 2010; McQuillin et al., 2011). Thus, the role of
copy-number variation in conferring risk for bipolar disorder
remains in question (Grozeva et al., 2010; Zhang et al., 2009).
Some of the earliest conclusive evidence for the role of rare
CNVs in psychiatric disorders has come from family-based
studies that examined the genomic burden of spontaneously
occurring (de novo) CNVs (Marshall et al., 2008; Sebat et al.,
2007; Xu et al., 2008). De novo CNVs have consistently shown
the strongest association with risk for autism (Itsara et al.,
2010; Levy et al., 2011; Pinto et al., 2010; Sanders et al., 2011)
or schizophrenia (Xu et al., 2008), with a 5- to 10-fold enrichment(A) De novo CNVs were identified from whole-genome scans of the child, mothe
(B) CNV validation and breakpoint refinement was performed by analysis of the t
region (200 bp spacing).
(C) Deletion breakpoints were determined by PCR and Sanger sequencing.
(D) UCSC genome browser tracks of known genes are shown to scale with a train patients as compared with controls. We reasoned that if rare
highly penetrant CNVs contribute to risk for bipolar disorder,
the genetic effect would be most evident for de novo mutations.
We further reasoned that the contribution of de novo CNVs to
risk of bipolar disorder would be greatest in patients with an
earlier disease onset (AAO % 18). We screened for de novo
CNVs R 10 kb in size in blood-derived DNAs from 788
subject-mother-father trios including subjects with diagnoses
of bipolar disorder and schizophrenia, and normal healthy
controls. Here, we show that rare de novo copy-number muta-
tions are significantly enriched in bipolar disorder and in
schizophrenia.
RESULTS
Our study sample included 788 subject-mother-father trios
with confirmed parentage. DNA from all subjects was derived
from whole blood. Details of the subjects are described in the
Supplemental Experimental Procedures (available online). Diag-
noses of subjects included bipolar disorder (n = 185, including
107 with an age at onset % 18), schizophrenia (n = 177), and
healthy controls (n = 426). While the primary disease focus of
this study was BD, the inclusion of an additional schizophrenia
cohort served first to replicate the one previous study of de
novo CNVs in SCZ (Xu et al., 2008) and second to enable a
valid comparison of patterns of de novo CNVs in BDwith another
disorder. In addition, a small set of autism spectrum disorder
(ASD) trios (n = 45), all of which had been included in a previous
study (Sebat et al., 2007) and three of which carried known de
novo CNVs, were included as a ‘‘positive control’’ to confirm
the sensitivity of our methods for detecting de novo events.
We performed high-resolution genome-wide copy-number
scans, using the NimbleGen HD2 array comparative genomic
hybridization (CGH) platform, on all subjects and their biological
parents. Data processing and CNV detection were performed
as described in Experimental Procedures. CNV call sets were
filtered based on probe ratio (%0.8 and R 1.2), number of
probes (R10), frequency (<1%), and confidence score (Supple-
mental Experimental Procedures, Tables S1 and S2, and Figures
S1 and S2). Rare CNVs that were present in subjects and not
in their parents were subsequently validated and fine mapped
using a custom tiling-resolution CGH array (Oxford Gene Tech-
nology) (Tables S3 and S4). Results for the genome-wide scans,
tiling array validations, and breakpoint sequencing are illustrated
by four examples: a deletion involving CMIP and PLCG2 genes
(Figure 1I) and an exonic deletion of LINGO2 gene (Figure 1II)
detected in subjects with a diagnosis of BD, and an intronic
deletion of CSMD3 gene (Figure 2I) and a deletion adjacent
to UGT8 gene (Figure 2II) detected in subjects with a diagnosis
of SCZ.
A total of 23 de novo CNVs were detected and validated in our
study sample, including fourteen deletions and nine duplicationsr, and father, using the NimbleGen HD2 platform.
rio using a custom Agilent microarray with dense probe coverage of the target
ck for de novo deletions displayed in red.
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Table 1. De Novo CNVs Detected in This Study
Diagnosis SampleID
Age at
Onset (yrs) Sex Cytoband Start End
CNV
Size (bp) CNV Type Genes
Breakpoint
Sequence
Bipolar disorder 420-10015 15 F 3q21.2 126663504 126720022 56519 deletion SNX4
Bipolar disorder 400-10117 21 F 3q29 197417247 198249463 832217 deletion 25 genes SegDup
Bipolar disorder 410-10124 11 M 5p15.1 17508759 17561308 52550 deletion SegDup
Bipolar disorder 410-10145 11 F 5q31.2 138051454 138254688 203235 duplication CTNNA1;
LRRTM2
Bipolar disorder 5459 17 F 9p24.1 5264155 7119082 1854928 duplication 15 genes SegDup
Bipolar disorder 5459 17 F 9p23 9855970 9927360 71391 duplication PTPRD
Bipolar disorder 410-10127 8 M 9p21.1 28639667 28696714 57048 deletion LINGO2 Unique
Bipolar disorder bbn-106-
01
23 M 16p11.2 29512728 30124017 611290 duplication 38 genes SegDup
Bipolar disorder 410-10145 11 F 16q22.3 73021657 73057216 35560 duplication AL833498;GLG1 SegDup
Bipolar disorder 410-10142 7 F 16q23.2 80019981 80399720 379740 deletion CMIP;BC040927;
PLCG2
SINE
Control SSC02546 F 13q33.1 101035498 101078525 43028 deletion ITGBL1
Control SSC00206 M 18p11.31-
p11.23
6479110 7904147 1425038 duplication 6 genes
Control SSC02714 F 19q13.12 42608251 42647120 38870 deletion ZNF569 SINE
Control SSC00695 M 19q13.33 54915631 54930771 15141 deletion
Schizophrenia 4822 21 M 1p36.33 755082 1266721 511640 deletion 31 genes SegDup
Schizophrenia 02-0047 20 F 4q26 115625575 115737638 112064 deletion Unique
Schizophrenia 02-0135 22 F 4q35.2 187892312 191152733 3260422 deletion 7 genes SegDup
Schizophrenia 3236 17 M 6p22.3 17639894 17988098 348205 duplication CAP2;FAM8A1;
NUP153;KIF13A
Schizophrenia 02-0135 22 F 7q36.1-
q36.3
151641965 158820241 7178277 duplication 41 genes
Schizophrenia 02-0022 12 M 8p21.2 25028902 25046800 17899 deletion
Schizophrenia 02-0104 22 F 8q23.3 113802932 113843685 40754 deletion CSMD3 SINE
Schizophrenia 6574 26 M 12q24.23 117065514 117132798 67285 deletion PEBP1;TAOK3
Schizophrenia 4295 24 M 22q11.21 18869860 20006782 1136923 duplication 32 genes SegDup
All 23 de novo CNVs discovered and validated in 788 trios are sorted by diagnosis and genomic location. Diagnosis denotes affected or unaffected
disease status. ‘‘SampleID’’ is a unique identifier for each subject. Age at onset and sex of subjects are listed. Cytological band and start and end
coordinates are listed for hg18 build. CNV length (‘‘CNV Size’’) in base pairs for deletions and duplications (‘‘CNV Type’’) is displayed. For each de
novo CNV, all overlapping annotated UCSC Known Genes are listed, and the presence of flanking segmental duplications within 15 kb of a CNV
boundary is indicated (SegDup). Breakpoint sequences were determined for an additional five deletions, and breakpoints consisted of either unique
sequence or short interspersed nuclear element (SINE) repeats.
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with a median size of 112 kb, and contained a median of two
genes.
About one-third (8/23) of de novo CNVs in our study were
flanked by segmental duplications (SDs) at one (6/23) or at
both boundaries (2/23). This class of CNV most likely occurredFigure 2. Detection, Validation, and Breakpoint Sequencing of De Nov
Representative examples of microarray data and sequencing results are provided
and 02-0047 (panel II).
(A) De novo CNVs were identified from whole-genome scans of the child, mothe
(B) CNV validation and breakpoint refinement was performed by analysis of the t
region (200 bp spacing).
(C) Deletion breakpoints were determined by PCR and Sanger sequencing.
(D) UCSC genome browser tracks of known genes are shown to scale with a traby nonallelic homologous recombination (NAHR) (Lupski,
1998). By contrast, the majority of de novo CNVs were not
flanked by SDs. Breakpoint sequences were obtained for five
deletions (Table 1). Junction sequences of three out of five
deletions were in short interspersed nuclear element (SINE)
repetitive elements and two deletions had unique sequenceso CNVs in SCZ
for deletions detected in two subjects with diagnoses of SCZ, 02-0104 (panel I)
r, and father, using the NimbleGen HD2 platform.
rio using a custom Agilent microarray with dense probe coverage of the target
ck for de novo deletions displayed in red.
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Table 2. De Novo CNVs Are Significantly Associated with Bipolar Disorder and Schizophrenia
Sample # Trios
# De Novo
CNVs
# Subjects with
De Novo CNVs
Rate of Subjects
with De Novo CNVs
Odds Ratio
[95% CI] p Value
Dels:Dups
(Ratio)
Bipolar 185 10 8 0.043 4.8 [1.4,16.0] 0.009 5: 5 (1)
AAO% 18 107 8 6 0.056 6.3 [1.7,22.6] 0.006
AAO > 18 76 2 2 0.026 2.9 [0.5,15.8] 0.22
Schizophrenia 177 9 8 0.045 5.0 [1.5,16.8] 0.007 6: 3 (2.0)
AAO% 18 59 2 2 0.034 3.7 [0.7,20.7] 0.158
AAO > 18 112 7 6 0.054 6.0 [1.7,21.5] 0.007
Controls 426 4 4 0.009 3: 1 (3)
The total number of de novo CNVs detected and the number subjects carrying a de novo event are listed. Cases are further stratified based on age
at onset (AAO) of BD and SCZ. p values were computed using a Fisher’s exact test of the number of subjects with and without de novo CNVs in cases
and controls.
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De Novo CNVs in Bipolar Disorder and Schizophreniaat their breakpoints. A 1 bp insertion occurred at one of the
breakpoints (see underlined base in Figure 2I). Notably, the
median size of SD and non-SD-mediated de novo CNVs was
722 kb and 67 kb respectively, consistent with previous studies
that have found differences in CNV size related to the underlying
mutational mechanism (Itsara et al., 2010; Stefansson et al.,
2008).
De novo CNVs were significantly associated with BD and SCZ
(Table 2). The rate of de novo mutation in controls was 0.9%
(4/426). This rate is consistent with estimates from previous
studies ranging from 0.5% to 3% (Conrad et al., 2010; Itsara
et al., 2010; Levy et al., 2011; Sebat et al., 2007; Xu et al.,
2008). The observed rate of de novo CNVs in bipolar disorder
subjects was 4.3% (8/185), a significant enrichment compared
with controls (p = 0.009, OR = 4.8 [1.4,16.0]). De novo CNVs
were also detected at a significantly higher rate (8/177, 4.5%)
in schizophrenia subjects than in controls (p = 0.007, OR = 5.0
[1.5,16.8]). These results provide significant evidence for anFigure 3. Survival Analysis of De Novo CNVs and Age at Onset in BD a
Weperformed a survival analysis/Kaplan-Meier test to analyze the effect of de nov
This test determines whether ‘‘time to diagnosis’’ differs systematically betwee
formalized by performing the Mantel-Haenszel test on the survival curves and re
956 Neuron 72, 951–963, December 22, 2011 ª2011 Elsevier Inc.association of de novo mutation with bipolar disorder and
confirm earlier reports of a high rate of de novo copy-number
mutation in schizophrenia (Xu et al., 2008).
We investigated the influence of age at onset on the fre-
quency of de novo mutations. After stratifying patients by age
at onset % 18, we observed a significantly higher rate of de
novo CNVs in early-onset BD (p = 0.006, OR = 6.3 [1.7,22.6],
Table 2). This difference was also nominally significant (p =
0.03) based on a survival analysis comparing AAO in subjects
with or without a de novo CNV (Figure 3A). By contrast, we did
not observe an effect of AAO on the frequency of de novo muta-
tions in schizophrenia (Table 2, Figure 3B).
We further reasoned that frequencies of de novo CNVs
might be influenced by the presence or lack of a family history
of mental illness, a hypothesis based on earlier findings by
our group and others that de novo CNVs occur more frequently
in sporadic cases of ASD (Marshall et al., 2008; Sebat et al.,
2007) and schizophrenia (Xu et al., 2008). We stratified subjectsnd SCZ
omutations on age at onset in BD (n = 185, panel A) and SCZ (n = 177, panel B).
n patients who have de novo mutations and those who do not. The test is
porting the resulting p value.
Table 3. Mutational Burden Analysis of Genic Rare Inherited CNVs in BD, SCZ, and Controls
CNV Size CNV Type Sample Group # Trios # CNVs
# CNVs
per Genome
Case/
Control Ratio
Wilcoxon
p Value
R100 kb Deletions & Duplications Controls 426 237 0.56
Familial BD 107 71 0.66 1.19 0.65
Sporadic BD 78 28 0.36 0.65 0.36
Familial SCZ 44 23 0.52 0.94 0.92
Sporadic SCZ 97 46 0.47 0.85 0.43
R100 kb Deletions Controls 426 75 0.18
Familial BD 107 18 0.17 0.96 0.90
Sporadic BD 78 10 0.13 0.73 0.50
Familial SCZ 44 7 0.16 0.90 0.97
Sporadic SCZ 97 18 0.19 1.05 0.55
R100 kb Duplications Controls 426 162 0.38
Familial BD 107 53 0.50 1.30 0.42
Sporadic BD 78 18 0.23 0.61 0.62
Familial SCZ 44 16 0.36 0.96 0.91
Sporadic SCZ 97 28 0.29 0.76 0.22
R500 kb Deletions & Duplications Controls 426 40 0.09
Familial BD 107 14 0.13 1.39 0.06
Sporadic BD 78 5 0.06 0.68 0.82
Familial SCZ 44 8 0.18 1.94 0.53
Sporadic SCZ 97 9 0.09 0.99 0.33
R500 kb Deletions Controls 426 13 0.03
Familial BD 107 2 0.02 0.61 0.95
Sporadic BD 78 2 0.03 0.84 0.73
Familial SCZ 44 1 0.02 0.74 0.42
Sporadic SCZ 97 3 0.03 1.01 0.62
R500 kb Duplications Controls 426 27 0.06
Familial BD 107 12 0.11 1.77 0.03
Sporadic BD 78 3 0.04 0.61 0.88
Familial SCZ 44 7 0.16 2.51 0.22
Sporadic SCZ 97 6 0.06 0.98 0.30
We tested for differences in global CNV burden between cases (BD or SCZ) and controls by comparing CNV rate, i.e., average number of CNVs
per genome. CNV burden was tested only for large (R100 kb) rare inherited CNVs that impacted one or more annotated UCSC known genes and
significance was estimated using Wilcoxon test. Uncorrected p values are listed for each test. Analyses were further stratified according to CNV
type (deletions and duplications separately), CNV size (R100 kb andR 500 kb), and family history of BD and SCZ cases.
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De Novo CNVs in Bipolar Disorder and Schizophreniabased on evidence of positive family history, defined as having
a first-degree relative with a diagnosis of bipolar I, bipolar II,
major depression, schizophrenia, schizoaffective disorder,
autism, or intellectual disability. In BD and SCZ cohorts,
rates of de novo mutation were not higher in sporadic cases as
compared with subjects with a positive family history (Table S5).
While de novo CNVs might have a stronger effect size, it is
quite plausible that inherited CNVs could also contribute to risk
for BD. Notably, inherited CNVs detected in this study included
variants at loci that have been previously linked to schizophrenia
(International Schizophrenia Consortium, 2008; Stefansson
et al., 2008), including a duplication at 1q21.1 in a subject with
bipolar disorder and a duplication and a deletion at 15q13.3
detected in subjects with bipolar disorder and schizophrenia,
respectively (Document S2, bed file). Therefore, we examinedthe burden of rare inherited CNVs overlapping with genes in
BD, SCZ, and controls, and subjects were stratified based on
family history. We observed a trend of enrichment for large
(R500 kb) inherited duplications in familial cases of bipolar
disorder (OR = 1.77, p = 0.03, Table 3). We did not observe an
enrichment of deletions in familial bipolar disorder. Likewise,
we did not observe a significant enrichment of deletions or
duplications in sporadic bipolar disorder or in schizophrenia
(Table 3). These results are consistent with a role for inherited
CNVs in familial BD, particularly for large duplications; however,
data from a much larger sample are needed to draw firm
conclusions.
We sought additional genetic evidence for the loci at which
we found de novo CNVs by performing follow-up analyses of
the 23 de novo CNV regions in additional cohorts and families.Neuron 72, 951–963, December 22, 2011 ª2011 Elsevier Inc. 957
Table 4. Gene Set Enrichment Analysis of De Novo CNVs in Schizophrenia
Category Database ID Term CNV Genes
De Novo CNVs (This Study)
Rare CNVs (from
Vacic et al., 2011)
DAVID Permutation PLINK-CNVa PLINK-CNV
GOTERM_
BP_FAT
GO:0021915 neural tube
development
MNX1, SHH, DVL1 0.029 0.003 0.045 0.612
GOTERM_
BP_FAT
GO:0030902 hindbrain
development
EN2, SDF4, SHH 0.023 0.006 0.045 0.831
GOTERM_
BP_FAT
GO:0045471 response to
ethanol
PEBP1, SDF4, SHH 0.026 0.008 0.016 0.207
GOTERM_
BP_FAT
GO:0051146 striated muscle cell
differentiation
AGRN, SHH, DVL1 0.047 0.025 0.153 0.040
INTERPRO IPR015915 Kelch-type beta
propeller
KLHL17, LZTR1,
KLHL22
0.031 0.027 0.164 0.002
GOTERM_
CC_FAT
GO:0019717 Synaptosome SNAP29, PEBP1, DVL1 0.037 0.032 0.122 0.140
GOTERM_
CC_FAT
GO:0045202 Synapse SNAP29, P2RX6, KLHL17,
PEBP1, AGRN, DVL1
0.009 0.043 0.145 0.001
GOTERM_
BP_FAT
GO:0007267 cell-cell signaling ISG15, PI4KA, PEBP1,
AGRN, VIPR2, SHH, DVL1
0.029 0.110 0.222 0.040
For genes within de novo CNVs, eight functional categories were identified as enriched (p value < 0.05) by primary analysis using DAVID. We further
tested enrichment of these eight categories in de novo CNVs using a permutation-based test for enrichment (case only) and using the pathway enrich-
ment test implemented in PLINK-CNV (case-control). Three out of eight categories were found to be enriched among de novo CNVs in SCZ by all three
tests (p < 0.05, shown in bold), including ‘‘neural tube development,’’ ‘‘hindbrain development,’’ and ‘‘response to ethanol.’’ We also tested association
of the eight categories in an independent case-control data set consisting of rare CNVs (>100 kb in size) from 8,290 SCZ cases and 7,431 controls using
PLINK-CNV enrichment test. Two categories, ‘‘synapse’’ and ‘‘kelch-type beta propeller,’’ were significantly enriched in cases relative to controls (after
correction for eight tests; p values shown in bold). p values from PLINK-CNV were derived from a two-sided parametric test.
a For analysis of de novo CNVs using PLINK-CNV, a one-sided empirical p value was derived based on permutation.
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multiple case-control studies, including the Bipolar Genome
Study (BiGS) and Molecular Genetics of Schizophrenia (MGS)
study (see Supplemental Experimental Procedures). De novo
CNV regions were tested for association with BD and SCZ
using a permutation-based method described previously (Vacic
et al., 2011) (see Supplemental Experimental Procedures). No
significant associations were detected in bipolar disorder
(Table S6A). In schizophrenia, three genomic regions were sig-
nificant (Table S6B), all corresponding to CNVs that have been
previously implicated in schizophrenia at 3q29 (Mulle et al.,
2010), 7q36.3 (Vacic et al., 2011), and 16p11.2 (McCarthy
et al., 2009).
Previous studies have reported that rare CNVs associatedwith
neuropsychiatric disorders are enriched for genes involved in
neurodevelopment (Walsh et al., 2008; Zhang et al., 2009).
Here we examined whether genes impacted by de novo CNVs
in SCZ and BD are enriched in specific functional categories.
Pathway enrichment analysis was performed on the sets of
genes overlapping with de novo CNVs in SCZ, BD, and controls
(see Experimental Procedures). Enrichment of functional classes
of genes was tested using the DAVID software (http://david.
abcc.ncifcrf.gov/), followed by two additional permutation-
based tests to correct for the known bias of CNVs toward
large genes (Raychaudhuri et al., 2010), one implemented as a
case-only analysis and a second implemented as a case-control
analysis in PLINK (http://pngu.mgh.harvard.edu/purcell/plink/
cnv.shtml#burden2).958 Neuron 72, 951–963, December 22, 2011 ª2011 Elsevier Inc.Based on the primary analysis using DAVID, eight functional
categories were enriched among de novo CNVs in SCZ (p <
0.05). Three were also found to be enriched based on permuta-
tion tests of de novo CNVs in cases and controls, including
‘‘neural tube development,’’ ‘‘hindbrain development,’’ and
‘‘response to ethanol’’ (Table 4). Genes involved in neurode-
velopment were not enriched among de novo CNVs in BD
(Table 5) or in controls (Table S7). We then extended our anal-
ysis of schizophrenia to a large independent data set of rare
(>100 kb) CNVs from 8,290 cases and 7,431 controls. Eight
categories were tested in the case-control sample using the
PLINK-CNV parametric test, and two categories, ‘‘synapse’’
and ‘‘Kelch-type beta propeller,’’ were significantly enriched
among rare variants in cases (Table 4). The case-control data
set did not provide significant support for an enrichment of
genes related to neural tube development or hindbrain devel-
opment. While the strength of evidence supporting specific
pathways differs between data sets, we do find evidence
consistent with our earlier observations that there is an enrich-
ment of ‘‘neurodevelopmental’’ and ‘‘synaptic’’ genes among
rare CNVs in SCZ (Walsh et al., 2008).
DISCUSSION
Here we find strong evidence implicating rare de novo CNVs in
genetic risk for bipolar disorder. We also confirm previous find-
ings that de novo CNVs occur at a significantly increased rate
in individuals with schizophrenia (Xu et al., 2008). Based on our
Table 5. Gene Set Enrichment Analysis of De Novo CNVs in Bipolar Disorder
Category Database ID Term CNV Genes DAVID
De Novo CNVs
(This Study)
Rare Cnvs
(from BiGS)
Permutation PLINK-CNVa PLINK-CNV
GOTERM_
BP_FAT
GO:0042129 regulation of
T cell proliferation
CORO1A, CD274,
PDCD1LG2, SPN
0.001 0.002 0.039 0.743
GOTERM_
BP_FAT
GO:0006644 phospholipid
metabolic process
CDIPT, PIGZ, PIGX,
PLCG2, PCYT1A
0.002 0.004 0.024 0.304
GOTERM_
BP_FAT
GO:0008360 regulation of
cell shape
ALDOA, CORO1A,
TAOK2
0.010 0.009 0.195 0.004
GOTERM_
CC_FAT
GO:0005783 endoplasmic
reticulum
SEZ6L2, ERMP1, CDIPT,
PIGZ, PIGX, ASPHD1,
PCYT1A, MLANA, FAM57B
0.028 0.039 0.058 0.400
PANTHER_
PATHWAY
P00005 Angiogenesis PAK2, MAPK3, PLCG2 0.032 0.046 0.014 0.565
GOTERM_
CC_FAT
GO:0031224 intrinsic to
membrane
GLG1, ERMP1, CDIPT, TM4SF19,
LRRC33, TMEM219, ZDHHC19,
FAM57B, LINGO2, SEZ6L2, KIAA1432,
PAK2, PRRT2, LRRTM2, C3ORF43,
C9ORF46, OSTALPHA, MLANA, SPN,
PTPRD, PIGZ, TAOK2, PIGX, MFI2,
GDPD3, PDCD1LG2, CD274, ASPHD1,
C16ORF54, KCTD13, MVP
0.007 0.052 0.061 0.627
GOTERM_
BP_FAT
GO:0007010 cytoskeleton
organization
ALDOA, CORO1A, PAK2,
TAOK2, PPP4C
0.033 0.121 0.309 0.014
For genes within de novo CNVs, seven functional categories were identified as enriched (p value < 0.05) by primary analysis using DAVID. We further
tested enrichment of these eight categories in de novo CNVs using a permutation-based test for enrichment (case only) and using the pathway enrich-
ment test implemented in PLINK-CNV (case-control). Three categories were found to be enriched among de novo CNVs in BD by all three tests (p <
0.05, shown in bold), including ‘‘regulation of T-cell proliferation,’’ ‘‘phospholipid metabolic process,’’ and ‘‘angiogenesis.’’ We also tested association
of the seven categories in an independent case control data set consisting of rare CNVs from 2,777 BD cases and 3,508 controls using PLINK-CNV
enrichment test. One category, ‘‘regulation of cell shape,’’ was significantly enriched in cases relative to controls (after correction for seven tests;
p values shown in bold). p values from PLINK-CNV were derived from a two-sided parametric test.
a For analysis of de novo CNVs using PLINK-CNV a one-sided empirical p value was derived based on permutation.
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earlier study by our coauthor (Xu et al., 2008), we estimate that
the overall frequency of de novo CNVs > 10 kb is approximately
4% in BD and 5%–10% in SCZ.
Two previous case-control studies have observed an enrich-
ment of rare CNVs in bipolar disorder and in subjects with an
early age at onset. However, the observed effects were small
(OR  1.3) and results from two other studies (Grozeva et al.,
2010; McQuillin et al., 2011) did not support these findings. In
our present study, which focused on the detection of de novo
CNVs using a family-based design, we observe a large effect
(OR > 4). This is consistent with other family-based studies of
autism (Levy et al., 2011; Marshall et al., 2008; Sanders et al.,
2011; Sebat et al., 2007) and schizophrenia (Xu et al., 2008,
2009) that have found a strong and robust genetic effect for de
novo mutations and a weaker genetic effect for inherited vari-
ants. The much greater effect size for de novo CNVs as
compared with inherited variants is consistent with de novo
mutations having a much higher proportion of risk alleles relative
to neutral alleles.
The high-density microarray platform used in this study
(2.1 million probes) provides good ascertainment of CNVs >
10 kb, a substantial improvement in sensitivity over earlierstudies of schizophrenia and autism. De novo CNVs of interme-
diate size (10–100 kb) were detected a rate of 3/426 (0.7%) in
controls and at a rate of 3/177 (1.7%) in schizophrenia and 5/
185 (2.7%) in bipolar disorder. Based on these observations,
intermediate-size CNVs may contribute to risk for these disor-
ders; however, they occur in a small fraction (2%–3%) of cases,
and the relative effect size is smaller than for large de novoCNVs.
We conclude that a small fraction of the heritability in schizo-
phrenia can be found among intermediate sized de novo struc-
tural variants.
The effect of de novo CNV on age at onset in bipolar disorder
was nominally significant. These preliminary findings and similar
results from previous studies (Priebe et al., 2011; Zhang et al.,
2009) suggest that individuals with an early onset of mania might
constitute a subclass of bipolar disorder in which there is a
greater contribution from rare alleles of large effect. Also consis-
tent with this notion is a previous study (Grigoroiu-Serbanescu
et al., 2001), which found that segregation of early-onset BD in
families was consistent with major gene effects, while familial
segregation of late-onset BD was consistent with a multifactorial
etiology.
The observed rate of de novo CNVs in cases of bipolar
disorder or schizophrenia with a positive family history of mentalNeuron 72, 951–963, December 22, 2011 ª2011 Elsevier Inc. 959
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De Novo CNVs in Bipolar Disorder and Schizophreniaillness was similar to the rate in sporadic cases. These results
contrast with earlier findings by our group and others in autism
(Marshall et al., 2008; Sebat et al., 2007) and schizophrenia (Xu
et al., 2008) documenting a higher rate of CNVs in sporadic
cases as compared with subjects who have a positive family
history. These early observations have not been universally repli-
cated (Kirov et al., 2011; Pinto et al., 2010). The reason for the
inconsistency is not clear. Possibly, the initial findings were
incorrect. Alternatively, variation in the observed effect could
occur by chance or it could potentially be explained by method-
ological differences between cohorts in how mental illness in
first-degree relatives is ascertained.
Pathway analysis of genes impacted by de novo CNVs in SCZ
lends support to independent findings from our group (Walsh
et al., 2008) and others (Kirov et al., 2011) that rare CNVs in
SCZ are enriched for genes that are related to synaptic function
and other genes involved in neurodevelopment. By contrast,
categories that were found to be enriched among de novo
CNVs in BD were related to cell proliferation and shape and
phospholipid metabolism (Table 5), the biological relevance of
which is far from obvious. Greater knowledge of the specific
genes involved in these disorders is needed to determine how
these pathways might relate to the pathophysiology of disease.
Our findings establish a contribution of rare CNVs and
spontaneous mutation to risk for bipolar disorder. This can
only be regarded as a starting point for studies of rare alleles in
BD and SCZ. A larger fraction of the heritability must lie among
different classes of alleles and will probably include rare and
de novo point mutations and small insertions or deletions (in-
dels). Indeed, preliminary studies of a small number of families
have found evidence that the exomic burden of de novo point
mutations is increased in schizophrenia (Girard et al., 2011; Xu
et al., 2011). While the degree of enrichment of exonic point
mutations in schizophrenia (0.73/exome in cases as compared
with 0.32/exome in controls in the combined sample) is modest
compared to the effect size for de novo CNVs, these results are
nevertheless intriguing. It is conceivable that the overall contri-
bution of de novo CNVs and point mutations to disease risk
could be substantial. High-throughput sequencing in a much
larger number of trios will be needed to determine the total
contribution of de novo mutation to risk for BD and SCZ in the
population.
EXPERIMENTAL PROCEDURES
The institutional review board of all participating institutions approved this
study and written informed consent from all subjects was obtained.
Microarray Data Processing and Segmentation
We performed high-resolution genome-wide copy-number scans, using the
Nimblegen HD2 2.1 M array CGH platform, on all subjects and their biological
parents. Complete details for microarray intensity data processing, CNV
discovery, and quality control (QC) measures for sample hybridizations are
provided in Supplemental Experimental Procedures. In brief, dual-color micro-
array hybridizations were performed at the service laboratory of Roche Nim-
bleGen according to the manufacturer’s specifications. Raw intensity data
were normalized in a two step process, first involving ‘‘spatial’’ normalization
which is an adjustment for regional variation in probe intensities across the
surface of the array, and second involving ‘‘invariant set normalization,’’ which
normalizes the distribution of intensities for test and reference samples. CNV960 Neuron 72, 951–963, December 22, 2011 ª2011 Elsevier Inc.detection from the Log2 probe ratios was performed using two segmentation
algorithms, HMMSeg and Genome Alteration Detection Analysis (GADA).
In addition, probe ratio data was used to identify and genotype common
copy-number polymorphisms (CNPs) using automated correlation- and
clustering-based methods (see Supplemental Experimental Procedures).
Stringent QC filters were applied to arrays and CNV calls to ensure that the
ascertainment of CNVs was consistent between subjects and their parents
(see Supplemental Experimental Procedures and Table S1).
Rare CNV Determination
We determined the population frequency of CNVs detected in our study
sample by comparison with CNV calls (based on R 50% reciprocal overlap
of its CNV length) from a larger reference population of 4,081 unrelated
subjects analyzed in our laboratory using the same array platform. Unrelated
subjects consisted of 3,309 population controls, 604 subjects with diagnosis
of schizophrenia, 154 subjects with mood disorders, and 14 subjects with
a diagnosis of ASD (Table S2). CNVs that were detected in > 1% of the refer-
ence population were excluded.
Rare CNVs were further filtered by three metrics: (1) Confidence score (CS),
(2) segmental duplication (SD) content, and (3) overlap with validated common
copy-number loci. CS was calculated using MeZOD, an outlier-detection-
based method published previously (McCarthy et al., 2009), where the rare
CNV call is assigned a p value based on the distribution of probe ratios across
the reference population. Thresholds for CS were then adjusted within each
size class of CNV to achieve a 5% rate of mendelian inconsistency across
all size classes (Figure S1). Second, we removed rare CNVs which had >
70% overlap with known SDs from the UCSC hg18 Human Genome browser
annotations. A SD filter is helpful because it eliminates regions where the exact
location, boundaries, and patterns of inheritance of the CNV calls are often
too difficult to determine from array CGH data due to the complexity of the
local genomic architecture. This final rare CNV call sets consisted of 3,856
CNVs in 788 offspring including BD, SCZ, and controls and in 45 ASD subjects
(Table S1).
Parentage Testing
Before examining the parent-child transmission of CNVs in trios, we first
confirmed parentage of all trios included in CNV analysis. We used geno-
types from 486 CNPs (see Supplemental Experimental Procedures) to test
relatedness. For each pair within a trio (i.e., mother-child, father-child, and
mother-father), genetic relatedness was tested by the Glaubitz Relationship
Score (GRS) (Glaubitz et al., 2003). Based on this test, first-degree relative
pairs (i.e., mother-child and father-child) were clearly distinguishable from
the distribution of GRS scores for unrelated individuals (i.e., mother-father
pairs) as shown in Figure S2. We applied a threshold of > 0.37 to define relat-
edness. Thirty-two families failed parentage testing, and the remaining
788 trios were included in our analysis. Pairwise relationship of all subjects
in 788 trios was confirmed using a second relatedness testing method,
Graphical Representation of Relationships (GRR, http://www.sph.umich.
edu/csg/abecasis/GRR/).
Identification of De Novo CNVs
The identification of rare de novo mutations from CNV data on families is
nontrivial. While CNV calls that show mendelian patterns of inheritance (which
is the overwhelming majority of CNVs in the genome) are quite reliable, the
fraction of CNV calls that are present in offspring and not in parents are en-
riched for technical errors, in particular false-positive calls (in the offspring)
and false-negative calls (in parents). In addition, the enrichment of such errors
is greater for smaller CNVs. To address these sources of error, we designed
a set of algorithms for de novo CNV identification in families. The false-positive
CNV call rate was controlled (maintained at 5%) for a wide range of CNV sizes
by adaptive filtering of confidence scores (CSs), as described above. In order
to minimize the number of false-negative calls in parents, the CNV region was
directly genotyped using the MeZOD, and a confidence score was used to
assign genotypes to the parents. Rare CNVs in children were called inherited
if the CS was % 0.04 in either of the two biological parents and de novo if
CS was > 0.04 in both biological parents. We identified 145 putative de novo
CNVs in 788 subjects including BD, SCZ, and controls.
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All putative de novo CNVs detected in our whole-genome scanswere indepen-
dently validated on second custom tiling array platform.
Array CGH
A custom Agilent 1M array was designed with dense coverage (average probe
spacing of 200 bp) of all putative de novo CNV regions. Samples were coded
and hybridizations were done in random order to avoid any plate effects.
Two-color hybridizations were performed with two micrograms of sample
and reference DNA (CHP-SKN-1) and hybridized to the array at the Oxford
Gene Technology service laboratory (Cambridgeshire, UK).
Array Data Processing
Raw intensity data were normalized by Oxford Gene Technology service lab
using Agilent’s recommended normalization method. Experiments with poor
derivative log2 ratio spread (DLRS > 0.2) were repeated. We received normal-
ized intensity data on all samples from Oxford Gene technology in one batch.
Probe Log2 Ratios were then standardized within each array.
CNV Detection
Detection of rare CNVswas performed usingMeZOD as follows. For each CNV
region that was defined in our whole-genome scans, we computed themedian
Z score of tiling array probes in each individual. The median of a region was
then standardized vertically across all individuals. We then assign deletion
genotypes using a Z score threshold of%2 and duplication genotypes using
a Z score threshold ofR +2. Positive CNV calls were further verified by manual
inspection of log2 ratios in the subject, mother, and father. Representative
examples of validated de novo deletions are shown in Figures 1 and 2. The
details of the number of putative de novo CNVs identified in BD, SCZ, and
controls and their validation by tiling array CGH are described in Table S3.
The rates of validations are presented in Table S4. The overall validation rate
of putative de novo CNVs was 16% (23/145). As expected, the validation
rate was highest for CNVs > 100 kb in size and lowest (3%) for CNVs that
were < 20 kb in size.
We evaluated the performance of our de novo CNV calling method by: i)
analyzing a small set of 45 ASD trios included in our previous CNV study (Sebat
et al., 2007) and, ii) by comparing results on validated control de novo CNVs
identified by our group with results from a recent study(Levy et al., 2011) by
Mike Wigler’s group. In 45 ASD trios we detected and validated all 3 de
novo CNVs that were identified in our previous study and in addition, we iden-
tified one novel de novo CNV 38 kb in size (Table S8). We compared our list of
validated control de novo CNVs with de novo CNVs reported by (Levy et al.,
2011) in the same 426 control trios using an entirely different informatics
approach to identify de novo CNVs. Both groups identified four validated de
novo CNVs in controls and therefore observed an identical rate (0.9%) of de
novo CNVs in 426 controls. Three out of four de novo events overlapped
between two groups. One de novo event that was unique to each group
was < 20 kb in size. These comparisons showed that our method had high
sensitivity in identifying de novo CNVs in different size classes.
Breakpoint Sequencing
CNV boundaries were estimated based on the probe (log2) ratio information
from tilling array CGH. PCR primers were then designed to amplify the break-
points of five de novo deletions. PCR was performed on genomic DNA from all
members of the trio. PCR products were sequenced by the Sanger method
using both forward and reverse primers specific for each de novo deletion.
Gene Set Enrichment Analysis of De Novo CNVs
We examined whether genes impacted by de novo CNVs in SCZ, BD, and
controls were enriched for specific functional categories. In addition, func-
tional categories found to be enriched within each diagnostic groupwere inter-
rogated in rare CNVs from large independent cases control data sets including
8,290 SCZ, 2,777 BD, and 7,431 controls.
For gene set enrichment analysis, we used 39 de novo CNVs including nine
in SCZ, ten in BD, four in our controls, and an additional 16 CNVs detected in
a previous study by Levy et al. (2011) in an independent set of control subjects
using the same array platform.We prefer to use only de novoCNVs as a control
set. Naturally occurring variants in the population do not make the ideal control
set for this analysis because the gene content of these CNVs is shaped by
natural selection and is not likely to be representative of random mutation.Gene set enrichment analyses was performed on the sets of genes
impacted by de novo CNVs in SCZ, BD, and controls. The primary step was
performed using ‘‘DAVID Bioinformatics Resources 6.7’’ website (http://
david.abcc.ncifcrf.gov/) using Gene Ontology terms—biological processes
(GO_BP), cellular components (GO_CC), and molecular functions
(GO_MF)—including KEGG, BioCarta, BBID, and Panther pathway databases
and by excluding pathway results containing < 3 CNV genes. We selected
the nonredundant pathways from DAVID with p value < 0.05 for further anal-
ysis by permutation-based test. Based on analysis using DAVID, eight cate-
gories were enriched among de novo CNVs in SCZ (Table 4), seven categories
were enriched among de novo CNVs in BD (Table 5), and nine categories
were enriched among de novo CNVs in controls (Table S7).
The enrichment test performed within the DAVID software does not correct
for certain biases of CNVs toward certain functional classes of genes and large
genes in particular. In order to correct for these biases we applied two permu-
tation-based tests to the pathways found to be enriched by DAVID. First, we
performed a case-only permutation-based test by constructing empirical
null distributions that took the CNV size distribution and gene number into
account. We randomly placed 10,000 sets of CNVs (same number of events,
size distribution) throughout the genome. Placement on any autosome was al-
lowed, but we sampled such that placement on chromosomes was weighted
in proportion to the total number of de novo CNVs observed on the respective
chromosome. We controlled for the number of genes impacted by CNVs by
discarding individual permutations that intersected with more or less than
the number of genes impacted in the observed data (± 10 genes). This proce-
dure led to 1,000–2,000 permutations of null hypothesis CNV sets each for the
bipolar, schizophrenia, and control de novo CNV sets. Significance for each of
the query pathways was assessed by counting the number of pathway genes
impacted by each null hypothesis CNV set, thus leading to a null distribution
against which we could compare the number of observed hits and calculate
enrichment p values.
Second we applied a case-control CNV enrichment test implemented in
PLINK (http://pngu.mgh.harvard.edu/purcell/plink/) to the eight gene sets
(pathways) associated with SCZ de novo CNVs and seven gene sets associ-
ated with BD de novo CNVs. For analysis of de novo CNVs using PLINK we
report the one-sided empirical p value based on 10,000 permutations. A cate-
gory was defined as ‘‘enriched’’ if nominally significant (p < 0.05) by all case-
only and case-control permutation tests. Pathway enrichment analysis was
also applied to de novoCNVs in control, and significancewasbasedon a single
(control only) permutation test.
We extended our analysis of pathways identified in this study (Tables 4, 5,
and S7) to rare CNVs from large case-controls studies of SCZ and BD. These
included rare CNVs from 8,290 SCZ cases and 7,431 controls from Vacic et al.
(2011), a combined sample of three studies from our group, MGS (Levinson
et al., 2011), and the International Schizophrenia Consortium (International
Schizophrenia Consortium, 2008), and a BD case-control data set consisting
of 2,777 cases and 3,508 controls from BiGS study (Smith et al., 2009).
Pathway enrichment was assessed using the case-control CNV enrichment
test implemented in PLINK.SUPPLEMENTAL INFORMATION
Supplemental Information includes eleven tables, three figures, Supplemental
Experimental Procedures, and a bed file and can be found with this article on-
line at doi:10.1016/j.neuron.2011.11.007.
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